Supernus Awarded Patents Covering Trokendi XR
Supernus Pharmaceuticals (NASDAQ: SUPN) today announced the issuance of two patents (8,298,576 and 8,298,580) by the US Patent and Trademark Office (USPTO) covering Trokendi XR™, its novel once-daily extended-release topiramate product. Both patents were issued by the USPTO on October 30, 2012.
"This is a very important development for us as we continue to build intellectual property protection for our products. Each of our epilepsy products, Trokendi XR™ and Oxtellar XR™, is now covered by two issued US patents," said Jack A. Khattar, President and CEO of Supernus.
Supernus has several additional patent applications for extended-release topiramate and extended-release oxcarbazepine pending in other geographic regions.